A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders

Objectives: In this 6-month open-label extension (OLE) of NCT01491035 (a 14-day, open-label, pharmacokinetic/safety lead-in study), the long-term safety and tolerability of vortioxetine (5–20 mg/day) were investigated in children and adolescents with a DSM-IV-TR™ diagnosis of depressive or anxiety d...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Child Adolesc Psychopharmacol
Main Authors: Findling, Robert L., Robb, Adelaide S., DelBello, Melissa P., Huss, Michael, McNamara, Nora K., Sarkis, Elias H., Scheffer, Russell E., Poulsen, Lis H., Chen, Grace, Lemming, Ole M., Auby, Philippe
Formato: Artigo
Idioma:Inglês
Publicado: Mary Ann Liebert, Inc. 2018
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5771527/
https://ncbi.nlm.nih.gov/pubmed/29035574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2017.0047
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares